1 1

Cell Signaling Institute

KPV: Anti-Inflammatory & Gut-Targeted Peptide

KPV: Anti-Inflammatory & Gut-Targeted Peptide

Home / Course / KPV: Anti-Inflammatory & Gut-Targeted Peptide

Context-Dependent Inflammation Control via PepT1 Mucosal Targeting

KPV (Lysine–Proline–Valine) is a naturally occurring tripeptide derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH). It retains α-MSH’s anti-inflammatory and immunomodulatory properties without its pigmentation side effects.

KPV’s defining feature is context-dependent activity: it preferentially enters inflamed tissue via the PepT1 transporter while remaining largely inert in healthy tissue. This makes oral liposomal delivery mechanistically optimal for GI inflammation — the oral route delivers intact peptide directly to inflamed intestinal mucosa where PepT1 is upregulated.

Evidence Tier: C (Emerging) — robust preclinical data across multiple colitis models; strong mechanistic plausibility via PepT1/NF-κB pathway; no published human efficacy data.

$199.00 USD
$199.00 USD
Sale Coming Soon
View full details

What You’ll Be Able To Do

  • Explain KPV’s inflammation-dependent cellular entry via PepT1 and why oral delivery is mechanistically superior for GI indications
  • Describe NF-κB and MAPK inhibition as core intracellular signaling effects and distinguish immune modulation from immunosuppression
  • Design oral liposomal KPV protocols (500 mcg/day starting dose) for GI inflammation, mucosal barrier dysfunction, and inflammatory skin conditions
  • Apply KPV-specific exclusion criteria: pregnancy, active malignancy, severe immunosuppression, concurrent biologics, and MCAS/histamine sensitivity
  • Evaluate combination strategies with BPC-157 for concurrent barrier repair and cytokine modulation

Clinical Focus Areas

Gastrointestinal Inflammation — IBD, colitis, mucosal barrier dysfunction. NF-κB inhibition and mucosal healing. PepT1-mediated gut uptake provides a direct mechanistic rationale for oral delivery.

Inflammatory Skin Conditions — Eczema, psoriasis, dermatitis. Topical models showing cytokine reduction and barrier support.

Immune Dysregulation — Cytokine excess patterns (TNF-α, IL-6, IL-1β, IL-8 reduction). Context-dependent modulation — active in inflamed tissue, inert in healthy tissue.

Epithelial Barrier Integrity — Tight junction stabilization, epithelial cell survival, and accelerated mucosal healing across GI and skin applications.

Who This Is For

Clinicians managing patients with GI inflammation, mucosal barrier dysfunction, or inflammatory presentations where NF-κB-driven cytokine excess is a clinical target.

Prerequisite: CSI Foundations (complimentary)

Course Details

Format: Self-paced, interactive online module via Reach 360

Time to Complete: Approximately 1 hour

Lessons: 7

Price: $199

Includes: Dosing & Protocol Desk Guide, Clinical Decision Tree, Evidence Reference Card, Competency Assessment

Frequently Asked Questions

Why is oral liposomal the primary route for KPV?

KPV is transported into cells via PepT1, a transporter significantly upregulated in inflamed intestinal mucosa. Oral liposomal delivery places intact, protected peptide directly at this uptake site. For GI indications, oral isn’t just acceptable; it’s mechanistically superior to injectable, which bypasses the gut mucosa entirely.

Can KPV be combined with BPC-157?

Yes. KPV targets inflammation (NF-κB inhibition, cytokine suppression) while BPC-157 targets tissue repair (angiogenesis, fibroblast activation). The mechanisms are complementary, not redundant — making this a common combination for GI healing programs.

Is KPV immunosuppressive?

No. KPV modulates inflammation without suppressing immune function. It reduces pro-inflammatory cytokines but does not increase IL-10 or suppress T-cell activity. This distinction is clinically important and is covered in detail in the cell signaling module.